VTv Therapeutics's Cadisegliatin Program For Type 1 Diabetes Placed On Clinical Hold, Stock Tanks
26/7 23:46
(RTTNews) - vTv Therapeutics Inc. (VTVT), Friday announced that the United States Food and Drug Administration (FDA) has placed a clinical hold on the cadisegliatin clinical program which includes the ongoing CATT1 Phase 3 trial in type 1 diabetes. Shares tanked 36% in the after-...